Washington now has a way to license bespoke gene editing and a channel for Medicaid to buy it, and the buying side is the less developed of the two. The guidance turns the February plausible mechanism framework, which already allowed several mutations in one application, into licence mechanics. The Medicaid model still covers one disease and two manufacturers, and CMS’s first findings speak to administrative burden and negotiating leverage, with no figures on patients treated.

• Genome editing developers: the platform becomes the unit of approval. A sponsor that draws its feature space wide enough in the first BLA can add later patients’ variants on in vitro data, so the first licence carries the cost and each later variant is cheap. The commercial test moves to whether payers will contract for a variant with no clinical trial of its own behind it.
• State Medicaid programmes and rare-disease manufacturers: pooling is the leverage. CMS negotiates once and states pool their beneficiaries, which for an ultra-rare disease spread across 34 participants is the only real bargaining power most states will have. Manufacturers of approved therapies can apply too, and will weigh supplemental rebates and a standard access policy against faster, uniform Medicaid coverage.
• Signposts: the request for applications, the docket and the leadership. Watch which conditions the CMS request names, the comments on docket FDA-2026-D-11783, and whether a programme launched in February under Marty Makary and Vinay Prasad keeps its pace under Acting Commissioner Kyle Diamantas and CBER director Karim Mikhail.